Jean Francois Tamby, MD MBA
About Jean Francois Tamby, MD MBA
Jean Francois Tamby, MD MBA, serves as the Vice President of Clinical Development for ATTR Cardiomyopathy and Acoramidis at BridgeBio in San Francisco. He has extensive experience in clinical research and development, having held various leadership roles at notable pharmaceutical companies including Sanofi, Aventis, and MyoKardia.
Current Role at BridgeBio
Jean Francois Tamby serves as the Vice President of Clinical Development for ATTR Cardiomyopathy and Acoramidis at BridgeBio. He has held this position since 2021, contributing to the advancement of clinical strategies and development processes in San Francisco, California. His role involves overseeing clinical trials and ensuring the effective development of therapies targeting cardiomyopathy.
Previous Experience in Clinical Research
Tamby has extensive experience in clinical research, having worked in various roles at Sanofi and its predecessor companies. He served as the Clinical Research Director for Oncology from 2006 to 2010, focusing on VEGF inhibitors and taxanes. He later became the Senior Director for Safety Surveillance and Risk Management in Global Pharmacovigilance and Epidemiology from 2010 to 2012, and then the Senior Director for CV/Metabolism from 2012 to 2017, where he worked on significant cardiovascular projects.
Educational Background
Tamby earned his MD in Cardiovascular Specialty from Université Paris Descartes, completing his residency at Paris Hospitals from 1984 to 1990. He furthered his education by obtaining a Medical Oncology Diploma from Institut Gustave Roussy between 2006 and 2007. Additionally, he holds an MBA from The Wharton School, which he completed from 1999 to 2001.
Career Progression
Tamby's career began at Aventis Pharmaceuticals, where he was the Head of North America Clinical Operations from 2000 to 2001. He transitioned to Sanofi-aventis as the Clinical Research Director for Cardiovascular/Thrombosis from 2002 to 2005. After his tenure at Sanofi, he worked at MyoKardia as Vice President of Clinical Science from 2017 to 2020, focusing on heart failure and cardiomyopathy, before briefly joining Bristol Myers Squibb in 2021.